Artificial Pancreas Device Systems for the Closed-Loop Control of Type 1 Diabetes: What Systems Are in Development?

Sara Trevitt, Sue Simpson, Annette Wood, Sara Trevitt, Sue Simpson, Annette Wood

Abstract

Background: Closed-loop artificial pancreas device (APD) systems are externally worn medical devices that are being developed to enable people with type 1 diabetes to regulate their blood glucose levels in a more automated way. The innovative concept of this emerging technology is that hands-free, continuous, glycemic control can be achieved by using digital communication technology and advanced computer algorithms.

Methods: A horizon scanning review of this field was conducted using online sources of intelligence to identify systems in development. The systems were classified into subtypes according to their level of automation, the hormonal and glycemic control approaches used, and their research setting.

Results: Eighteen closed-loop APD systems were identified. All were being tested in clinical trials prior to potential commercialization. Six were being studied in the home setting, 5 in outpatient settings, and 7 in inpatient settings. It is estimated that 2 systems may become commercially available in the EU by the end of 2016, 1 during 2017, and 2 more in 2018.

Conclusions: There are around 18 closed-loop APD systems progressing through early stages of clinical development. Only a few of these are currently in phase 3 trials and in settings that replicate real life.

Keywords: algorithm; artificial pancreas; closed-loop control; device system; glycemic control; type 1 diabetes.

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

© 2015 Diabetes Technology Society.

Figures

Figure 1.
Figure 1.
The 6 developmental stages of artificial pancreas device systems (copyright JDRF).

References

    1. Kovatchev BP, Renard E, Cobelli C, et al. Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas. Diabetes Care. 2014;37:1789-1796.
    1. Ly TT, Breton MD, Keith-Hynes P, et al. Overnight glucose control with an automated, unified safety system in children and adolescents with type 1 diabetes at diabetes camp. Diabetes Care. 2014;37(8):2310-2316.
    1. Brown SA, Kovatchev BP, Breton MD, et al. Multinight “bedside” closed-loop control for patients with type 1 diabetes. Diabetes Technol Ther. 2015;17(3):203-209.
    1. Kowalski A. Pathway to artificial pancreas systems revisited: moving downstream. Diabetes Care. 2015;28:1036-1043.
    1. JDRF. Artificial pancreas project research: artificial pancreas project plan. Reproduced with permission. Available at: .
    1. Thabit H, Tauschmann M, Allen JM, et al. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med. September 17, 2015. doi:10.1056/NEJMoa1509351.
    1. Kropff J, Del Favero S, Place J, et al. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol. September 29, 2015. doi:10.1016/S2213-8587(15)00335-6.
    1. van Bon A, Luijf YM, Koebrugge R, Koops R, Hoekstra JB, DeVries JH. Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours. Diabetes Technol Ther. 2014;16(3):131-136.
    1. Nimri R, Muller I, Atlas E, et al. MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. Diabetes Care. 2014;37 (11):3025-3032.
    1. Ziegler C, Liberman A, Nimri R, et al. Reduced worries of hypoglycaemia, high satisfaction, and increased perceived ease of use after experiencing four nights of MD-Logic artificial pancreas at home (DREAM4). Diabetes Res. 2015;2015:590308.
    1. Thabit H, Lubina-Soloman A, Stadler M, et al. Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. Lancet Diabetes Endocrinol. 2014;2(9):701-709.
    1. Hovorka R, Elleri D, Thabit H, et al. Overnight closed-loop insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care. 2014;37 (5):1204-1211.
    1. Thabit H, Tauschmann M, Allen JM, et al. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med. September 17, 2015. doi:10.1056/NEJMoa1509351.
    1. Thabit H, Elleri D, Leelarathna L, et al. Unsupervised home use of overnight closed-loop system over 3 to 4 weeks: pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes. Diabetes Obes Metab. 2015;17:452-458.
    1. Leelarathna L, Dellweg S, Mader JK, et al. Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three-center randomized crossover study. Diabetes Care. 2014;37(7):1931-1937.
    1. Leelarathna L, Dellweg S, Mader JK, et al. Assessing the effectiveness of 3 months day and night home closed-loop insulin delivery in adults with suboptimally controlled type 1 diabetes: a randomised crossover study protocol. BMJ Open. 2014;4(9):e006075. doi:10.1136/bmjopen-2014-006075.
    1. Skyler JS. T1DM in 2014: progress towards a bionic pancreas. Nat Rev Endocrinol. 2015;11:75-76.
    1. Legault L. Is the artificial pancreas coming to a home near you? Lancet Diabetes Endocrinol. September 29, 2015. doi:10.1016/S2213-8587(15)00369-1.
    1. National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Disease—DP3 type 1 diabetes targeted research award. Available at: .
    1. Barnard KD, Pinkser JE, Oliver N, Astle A, Dassau E, Kerr D. Future artificial pancreas technology for type 1 diabetes: what do users want? Diabetes Technol Ther. 2015;17(5):311-315.
    1. NIHR Horizon Scanning Research & Intelligence Centre. Closed-loop artificial pancreas device systems in development for type 1 diabetes. March 27, 2015. Available at: .
    1. van Bon A, Luijf YM, Koebrugge R, Koops R, Hoekstra JB, DeVries JH. Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours. Diabetes Technol Ther. 2014;16(3):131-136.
    1. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med. 2014;371:313-325.
    1. El-Khatib FH, Russell SJ, Magyar KL, et al. Autonomous and continuous adaptation of a bihormonal bionic pancreas in adults and adolescents with type 1 diabetes. Clin Endocrinol Metab. 2014;99(5):1701-1711.
    1. Nimri R, Muller I, Atlas E, et al. MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. Diabetes Care. 2014;37 (11):3025-3032.
    1. Ziegler C, Liberman A, Nimri R, et al. Reduced worries of hypoglycaemia, high satisfaction, and increased perceived ease of use after experiencing four nights of MD-Logic artificial pancreas at home (DREAM4). Diabetes Res. 2015;2015:590308, 8 pages.
    1. Del Favero S, Place J, Kropff J, Messori M, Keith-Hynes P, Visentin R. Multicenter outpatient dinner/overnight reduction of hypoglycemia and increased time of glucose in target with a wearable artificial pancreas using modular model predictive control in adults with type 1 diabetes. Diabetes Obes Metab. 2015;17(5):468-476.
    1. Nimri R, Phillip M. Artificial pancreas: fuzzy logic and control of glycemia. Curr Opin Endocrinol Diabetes Obes. 2014;21(4):251-256.
    1. Nimri R, Muller I, Atlas E, et al. Night glucose control with MD-Logic artificial pancreas in home setting: a single blind, randomized crossover trial—interim analysis. Pediatr Diabetes. 2014;15:91-99.
    1. Oron T, Farfel A, Muller I, et al. A remote monitoring system for artificial pancreas support is safe, reliable, and user friendly. Diabetes Technol Ther. 2014;16(11):699-705.
    1. Thabit H, Tauschmann M, Allen JM, et al. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med. September 17, 2015. doi:10.1056/NEJMoa1509351.
    1. Thabit H, Lubina-Soloman A, Stadler M, et al. Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. Lancet Diabetes Endocrinol. 2014;2(9):701-709.
    1. Hovorka R, Elleri D, Thabit H, et al. Overnight closed-loop insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care. 2014;37 (5):1204-1211.
    1. Thabit H, Tauschmann M, Allen JM, et al. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med. September 17, 2015. doi:10.1056/NEJMoa1509351.
    1. Thabit H, Elleri D, Leelarathna L, et al. Unsupervised home use of overnight closed-loop system over 3 to 4 weeks—pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes. Diabetes Obes Metab. 2015;17:452-458.
    1. Leelarathna L, Dellweg S, Mader JK, et al. Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three-center randomized crossover study. Diabetes Care. 2014;37(7):1931-1937.
    1. Leelarathna L, Dellweg S, Mader JK, et al. Assessing the effectiveness of 3 months day and night home closed-loop insulin delivery in adults with suboptimally controlled type 1 diabetes: a randomised crossover study protocol. BMJ Open. 2014;4(9):e006075. doi:10.1136/bmjopen-2014-006075.
    1. Kovatchev BP, Renard E, Cobelli C, et al. Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas. Diabetes Care. 2014;37:1789-1796.
    1. Ly TT, Breton MD, Keith-Hynes P, et al. Overnight glucose control with an automated, unified safety system in children and adolescents with type 1 diabetes at diabetes camp. Diabetes Care. 2014;37(8):2310-2316.
    1. Brown SA, Kovatchev BP, Breton MD, et al. Multinight “bedside” closed-loop control for patients with type 1 diabetes. Diabetes Technol Ther. 2015;17(3):203-209.
    1. Kropff J, Del Favero S, Place J, et al. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol. September 29, 2015. doi:10.1016/S2213-8587(15)00335-6.
    1. Haidar A, Legault L, Matteau-Pelletier L, et al. Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2015;3:595-604.
    1. Haidar A, Legault L, Messier V, Mitre TM, Leroux C, Rabasa-Lhoret R. Comparison of dual-hormone artificial pancreas, single hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open label randomised controlled crossover trial. Lancet Diabetes Endocrinol. 2015;3(1):17-26.
    1. Harvey RA, Dassau E, Bevier WC, et al. Clinical evaluation of an automated artificial pancreas using Zone-Model Predictive control and health monitoring system. Diabetes Technol Ther. 2014;16(6):348-357.
    1. Dassau E, Brown SA, Basu A, et al. Adjustment of open-loop settings to improve closed-loop results in type 1 diabetes: a multicentre randomized trial. J Clin Endocrinol Metab. 2015;100:3878-3886.
    1. Zisser H, Renard E, Kovatchev B, et al. Multicenter closed-loop insulin delivery study points to challenges for keeping blood glucose in a safe range by a control algorithm in adults and adolescents with type 1 diabetes from various sites. Diabetes Technol Ther. 2014;16(10):613-622.
    1. Chase HP, Doyle FJ, Zisser H, et al. Multicenter closed-loop/hybrid meal bolus insulin delivery with type 1 diabetes. Diabetes Technol Ther. 2014;16(10):623-632.
    1. diaTribe. Medtronic’s predictive low glucose suspend in the US in 2016, hybrid closed loop by 2017? January 23, 2015. Available at: .
    1. Bakhtiania PA, El Youssef A, Duella AK, et al. Factors affecting the success of glucagon delivered during an automated closed-loop system in type 1 diabetes. Diabetes Complications. 2015;29(1):93-98.
    1. Jacobs PG, El Youssef J, Castle J, et al. Automated control of an adaptive bi-hormonal, dual-sensor artificial pancreas and evaluation during inpatient studies. IEEE Transact Biomed Eng. 2014;61(10):2569-2581.
    1. Reddy M, Herrero P, El Sharkawy M, et al. Metabolic control with the bio-inspired artificial pancreas (BiAP) in adults with type 1 diabetes: a 24-hour randomised controlled cross-over study. Diabetes Technol Ther. 2015;17:A20-A21.
    1. Reddy M, Herrero P, El Sharkawy M, et al. Clinical evaluation of the bio-inspired artificial pancreas (BiAP) without meal announcement in adults with type 1 diabetes. Diabetes Technol Ther. 2015;17:A45-A46.
    1. Reddy M, Herrero P, Sharkawy M, et al. Feasibility study of a bio-inspired artificial pancreas in adults with type 1 diabetes. Diabetes Technol Ther. 2014;16(8):550-557.
    1. Turksoy K, Samadi S, Feng J, Littlejohn E, Quinn L, Cinar A. Meal-detection in patients with type 1 diabetes: a new module for the multivariable adaptive artificial pancreas control system. J Biomed Health Info. 2015;99:2168-2194.
    1. Turksoy K, Quinn L, Littlejohn E, Cinar A. An integrated multivariable artificial pancreas control system. J Diabetes Sci Technol. 2014;8(3):498-507.
    1. Turksoy K, Quinn L, Littlejohn E, Cinar A. Multivariable adaptive identification and control for artificial pancreas systems. IEEE Transact Biomed Eng. 2014;61(3):883-891.
    1. Mauseth R, Lord SM, Hirsch IB, Kircher RC, Matheson DP, Greenbaum CJ. Stress testing of an artificial pancreas system with pizza and exercise leads to improvements in the system’s fuzzy logic controller. J Diabetes Sci Technol. 2015;9:1253-1259.
    1. Wolpert H, Kavanagh M, Atakov-Castillo A, Steil GM. The artificial pancreas: evaluating risk of hypoglycaemia following errors that can be expected with prolonged at-home use [published online ahead of print June 3, 2015]. Diabetic Med. doi:10.1111/dme.12823.
    1. Capel I, Rigla M, Garcıa-Saez G, et al. Artificial pancreas using a personalized rule-based controller achieves overnight normoglycemia in patients with type 1 diabetes. Diabetes Technol Ther. 2014;16(3):172-179.
    1. Quemerais MA, Doron M, Dutrech F, et al. Preliminary evaluation of a new semi-closed-loop insulin therapy system over the prandial period in adult patients with type 1 diabetes: the WP6.0 Diabeloop Study. J Diabetes Sci Technol. 2014;8(6):1177-1184.
    1. Borot S, Franc S, Cristante J, et al. Accuracy of a new patch pump based on a microelectromechanical system (MEMS) compared to other commercially available insulin pumps: results of the first in vitro and in vivo studies. J Diabetes Sci Technol. 2014;8(6):1133-1141.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다